This CME Activity has expired and is no longer available for credit.
Postmenopausal Vulvovaginal Atrophy: Breaking Down Barriers to Identification and Treatment
Time to Complete
June 11, 2014
June 11, 2015
The North American Menopause Society (NAMS) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Healthcare professionals who are not physicians who complete this activity will be issued a certificate of participation. They should consult their professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.
The North American Menopause Society (NAMS)
This on-demand CME webcast will explore practice barriers to the identification and optimal, individualized treatment of postmenopausal vulvovaginal atrophy (VVA), a major component of the condition now known as Genitourinary Syndrome of Menopause.
Videotaped interviews with 3 patients currently being treated for VVA are the centerpiece of this activity. The women share their unique perspectives on surmounting the various barriers they faced in obtaining relief for their VVA symptoms. These discussions center on provider/patient communication difficulties, lack of awareness regarding the urogenital manifestations of estrogen loss, and lack of knowledge of the availability of effective therapies.
Throughout the activity, two leading experts in menopause management describe how the practicing clinician can avoid the potential pitfalls in VVA diagnosis and management. A detailed review of the safety and efficacy of available treatments for the condition will be provided, as will a rationale for the need to tailor therapy to the needs of each patient.
This activity is intended for physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other healthcare providers who treat or counsel women at midlife and beyond.
After taking part in this educational activity, participants should be better able to:
Employ strategies to improve communication with peri- and post-menopausal women on issues related to vaginal and sexual health
Recognize symptoms of vulvovaginal atrophy and related complications of decreased estrogen levels postmenopause
Describe the risks and benefits of recommended treatments for VVA and relay this information to patients
Implement appropriate VVA therapy in line with evidence-based guidelines, taking into account the needs and preferences of each patient
Conflict Of Interest Disclosure Policy
NAMS asks all individuals involved in the development and presentation of continuing medical education (CME) activities to disclose all relationships with commercial interest. This information is disclosed to CME activity participants. NAMS has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose any discussion of unapproved use of pharmaceuticals and devices. Faculty disclosures are listed below under the Faculty heading.
Sheryl A. Kingsberg, PhD Chief, Division of Behavioral Medicine Department of Obstetrics and Gynecology University Hospitals/MacDonald Women’s Hospital Professor, Departments of Reproductive Biology and Psychiatry Case Western Reserve University School of Medicine Cleveland, OH
Sheryl A. Kingsberg, PhD, serves as a consultant to and is on the advisory boards of Apricus BioSciences, Emotional Brain, Novo Nordisk, Palatin Technologies, Inc., Pfizer Inc, Shionogi Inc., Sprout Pharmaceuticals Inc., SST Technologies, Teva, and Trimel Pharmaceuticals Corporation. She receives grant/research support from Palatin Technologies, Inc. and Trimel Pharmaceuticals Corporation.
James H. Liu, MD Arthur H. Bill Professor and Chair Department of Ob/Gyn University Hospitals/MacDonald Women’s Hospital Department of Reproductive Biology Case Western Reserve University School of Medicine Cleveland, OH
James H. Liu, MD, is a consultant for Ferring, Noven, Pfizer, and Shionogi.
Mary Jane Minkin, MD Clinical Professor Department of Obstetrics, Gynecology and Reproductive Sciences Yale University School of Medicine New Haven, CT
Mary Jane Minkin, MD, serves on the advisory board for Bayer, Enzymatic Therapeutics, Noven, Novo Nordisk, and Shionogi. She also is on the speakers' bureau for Shionogi.
David J. Portman, MD Director Columbus Center for Women’s Health Research Columbus, OH
David J. Portman, MD, serves on the advisory boards and consults for Shionogi, Pfizer, Noven, Teva, Sprout, Palatin Technologies, and Apricus BioSciences. He has received research grants from QuatRx, Pfizer, Palatin Technologies, AbbVie, Noven, and Warner-Chilcott. He is on the speakers' bureau for Shiongi, Noven, and Teva.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The North American Menopause Society (NAMS) and Haymarket Medical Education. NAMS is accredited by the ACCME to provide continuing medical education for physicians.
NAMS designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accredited Provider Disclosure
Penny Allen, NAMS Education Manager, has no financial relationships to disclose.
Publishing Staff Disclosures
Susan Basilico, Stacy Clapp, and Krista Sierra of HME have no financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Novo Nordisk, NAMS, and HME do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Novo Nordisk, NAMS, and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
If you have any questions relating to the accreditation of this activity, please contact The North American Menopause Society (NAMS).
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.